How many doses of the Recombinant Zoster Vaccine (RZV) are required?

The Recombinant Zoster Vaccine (RZV), commonly known by its brand name Shingrix, is designed to prevent herpes zoster (shingles) and is administered in a two-dose series. The first dose is given, followed by a second dose that is typically administered two to six months later. This two-dose regimen has been shown to provide strong and lasting protection against shingles and its complications.

The rationale for requiring two doses rather than one is rooted in the need to establish a more robust immune response. The second dose helps to enhance the body's immunological memory, ensuring better long-term immunity.

Other options suggest various single or multiple doses which do not align with current immunization guidelines for RZV. Research and data from clinical trials have consistently shown that the two-dose series is necessary to achieve optimal protection against shingles, unlike other vaccines that might require fewer doses or a different schedule.